To see all protocols that comply with the WHO Essential Medicine List 
 ADDIKD Carboplatin dosing:

For dosing carboplatin, ADDIKD recommends that:

  • Directly measured glomerular filtration rate (mGFR) is the preferred kidney function value in the Calvert formula​, especially where estimated kidney function may be unreliable for accurate therapeutic dosing.
  • Where mGFR is unavailable, eGFR adjusted to an individual’s body surface area (BSA-adjusted eGFR) is a suitable alternative for use in the Calvert formula.
  • Kidney function should not be capped at 125 mL/min for use in the Calvert formula.
  • Recalculation of carboplatin doses at each cycle is unnecessary, except when baseline kidney function (e.g., eGFR) alters by > 20% or when there is a change in the clinical status of the patient.

For further information refer the eviQ Factsheet around carboplatin dosing and the carboplatin drug monograph within the ADDIKD guideline. To assist with calculations, use the eviQ Estimated Glomerular Filtration Rate (eGFR) and carboplatin dose calculators.

Treatment must be initiated and supervised by specialist physicians experienced in the treatment of cancer using immunological agents. Before commencing immunotherapy treatment in any patient, clinicians should have an understanding of the immune-related adverse events (irAEs) associated with immunotherapy treatment and their management.

Check for clinical trials in this patient group. Link to Australian Clinical Trials website

The anticancer drug(s) in this protocol may have been included in the ADDIKD guideline. Dose recommendations in kidney dysfunction have yet to be updated to align with the ADDIKD guideline. Recommendations will be updated once the individual protocol has been evaluated by the reference committee. For further information refer to the ADDIKD guideline. To assist with calculations, use the eviQ Estimated Glomerular Filtration Rate (eGFR) calculator.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

01 Mar 2024